{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:23:49Z","timestamp":1781670229649,"version":"3.54.5"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.mcna.2016.01.005","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T08:31:59Z","timestamp":1458289919000},"page":"535-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Diabetes Care After Transplant"],"prefix":"10.1016","volume":"100","author":[{"given":"Amisha","family":"Wallia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Illuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mcna.2016.01.005_bib1","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.2337\/dc13-0770","article-title":"Adverse outcomes after noncardiac surgery in patients with diabetes: a nation-wide population-based retrospective study","volume":"36","author":"Yeh","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.mcna.2016.01.005_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diacare.25.3.583","article-title":"Posttransplantation diabetes: a systematic review of the literature","volume":"25","author":"Montori","year":"2002","journal-title":"Diabetes Care"},{"issue":"10 Suppl","key":"10.1016\/j.mcna.2016.01.005_bib3","first-page":"SS3","article-title":"New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"issue":"19","key":"10.1016\/j.mcna.2016.01.005_bib4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa011300","article-title":"Intensive insulin therapy in the critically ill patients","volume":"345","author":"Van den Berghe","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mcna.2016.01.005_bib5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMoa0810625","article-title":"Intensive versus conventional glucose control in critically ill patients","volume":"360","author":"Finfer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.01.005_bib6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1007\/s00134-009-1585-2","article-title":"Prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study","volume":"35","author":"Preiser","year":"2009","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.mcna.2016.01.005_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jss.2007.02.019","article-title":"Effect of intraoperative hyperglycemia during liver transplantation","volume":"140","author":"Ammori","year":"2007","journal-title":"J\u00a0Surg Res"},{"issue":"7","key":"10.1016\/j.mcna.2016.01.005_bib8","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/00007890-200110150-00024","article-title":"Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study","volume":"72","author":"Thomas","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.mcna.2016.01.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-1-1","article-title":"Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes","volume":"1","author":"Thomas","year":"2000","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.mcna.2016.01.005_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/TP.0b013e3181c3c2ff","article-title":"Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection","volume":"89","author":"Wallia","year":"2010","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.mcna.2016.01.005_bib11","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1210\/jc.2012-1979","article-title":"A\u00a0randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes","volume":"97","author":"Hermayer","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.mcna.2016.01.005_bib12","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4158\/EP13463.OR","article-title":"The association between glycemic control and clinical outcomes after kidney transplantation","volume":"20","author":"Ramirez","year":"2014","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.mcna.2016.01.005_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4158\/EP10343.OR","article-title":"Glycemic control by a glucose management service and infection rates following liver transplantation","volume":"17","author":"Wallia","year":"2011","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.mcna.2016.01.005_bib14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1204942","article-title":"Hypoglycemia and risk of death in critically ill patients","volume":"367","author":"Finfer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association Consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib16","first-page":"274","article-title":"A\u00a0systematic review of failures in handoff communication during intrahospital transfers","volume":"37","author":"Ong","year":"2011","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"10.1016\/j.mcna.2016.01.005_bib17","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1001\/jama.2014.5951","article-title":"Insulin therapy for type 2 diabetes mellitus","volume":"311","author":"Wallia","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mcna.2016.01.005_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.transproceed.2007.03.030","article-title":"Association of hyperglycemia on allograft function in the early period after renal transplantation","volume":"39","author":"Ganji","year":"2007","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.mcna.2016.01.005_bib19","first-page":"23","article-title":"Early hyperglycemia after allogenic kidney transplantation: does it induce infections","volume":"12","author":"Hosseini","year":"2007","journal-title":"Ann Transplant"},{"issue":"4","key":"10.1016\/j.mcna.2016.01.005_bib20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1523-1755.2002.kid582.x","article-title":"Patient survival after renal transplantation: IV. Impact of post-transplant diabetes","volume":"62","author":"Cosio","year":"2002","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1034\/j.1600-6143.2003.00082.x","article-title":"Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients","volume":"3","author":"Woodward","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.mcna.2016.01.005_bib22","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2016.01.005_bib23","first-page":"S1","article-title":"Standards of medical care in diabetes\u20132016","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.mcna.2016.01.005_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","author":"Van Raalte","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.mcna.2016.01.005_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ndt\/gfs583","article-title":"Novel views on new-onset diabetes after transplantation: development, prevention and treatment","volume":"28","author":"Hecking","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1053\/j.ajkd.2004.03.020","article-title":"New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management","volume":"43","author":"Markell","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/00007890-200109270-00015","article-title":"Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality","volume":"72","author":"Baid","year":"2001","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus","volume":"13","author":"Bloom","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.mcna.2016.01.005_bib29","first-page":"269096","article-title":"New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOS\/OPTN Database","volume":"2013","author":"Yadav","year":"2013","journal-title":"J\u00a0Transplant"},{"issue":"7","key":"10.1016\/j.mcna.2016.01.005_bib30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00007890-199710150-00008","article-title":"Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age","volume":"64","author":"Hjelmesaeth","year":"1997","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/TP.0b013e3182094a33","article-title":"Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction","volume":"91","author":"Rostambeigi","year":"2011","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.mcna.2016.01.005_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A\u00a0long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.mcna.2016.01.005_bib34","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib35","first-page":"465","article-title":"Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience","volume":"7","author":"Xu","year":"2008","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"2","key":"10.1016\/j.mcna.2016.01.005_bib36","first-page":"146","article-title":"Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature","volume":"21","author":"Ghisdal","year":"2008","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.mcna.2016.01.005_bib37","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.2337\/db13-0106","article-title":"Evidence for rapamycin toxicity in pancreatic \u03b2-cells and a review of the underlying molecular mechanisms","volume":"62","author":"Barlow","year":"2013","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.mcna.2016.01.005_bib38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.tp.0000195770.31960.18","article-title":"Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs","volume":"81","author":"Araki","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.mcna.2016.01.005_bib39","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/ajt.12852","article-title":"Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis","volume":"14","author":"Murakami","year":"2014","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.mcna.2016.01.005_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.1Q537","article-title":"Belatacept: a new biologic and its role in kidney transplantation","volume":"46","author":"Su","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.mcna.2016.01.005_bib41","article-title":"Belatacept for kidney transplant recipients","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2016.01.005_bib42","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized Study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.mcna.2016.01.005_bib43","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.2337\/dc14-0479","article-title":"Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib44","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes 2015: a patient centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib46","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc12-2067","article-title":"Can new-onset diabetes after kidney transplant be prevented?","volume":"36","author":"Chakkera","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc11-1230","article-title":"New-onset diabetes after renal transplantation. Risk assessment and management","volume":"35","author":"Ghisdal","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/tri.12042","article-title":"Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation","volume":"26","author":"Shabir","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.mcna.2016.01.005_bib49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-6143.2011.03504.x","article-title":"Chronic calcineurin inhibitor nephrotoxicity\u2013lest we forget","volume":"11","author":"Chapman","year":"2011","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.mcna.2016.01.005_bib50","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/j.1552-4604.1995.tb04033.x","article-title":"Kidney function and age are both predictors of pharmacokinetics of metformin","volume":"35","author":"Sambol","year":"1995","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.mcna.2016.01.005_bib51","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease. A systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.01.005_bib52","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.1600-6143.2011.03550.x","article-title":"Should metformin be our antiglycemic agent of choice post-transplantation?","volume":"11","author":"Sharif","year":"2011","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.mcna.2016.01.005_bib53","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4158\/EP.14.8.979","article-title":"Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients","volume":"14","author":"Kurian","year":"2008","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.6002\/ect.2013.0018","article-title":"Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant","volume":"11","author":"Soliman","year":"2013","journal-title":"Exp Clin Transplant"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s002280050403","article-title":"Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function","volume":"53","author":"Jonsson","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.mcna.2016.01.005_bib56","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s001250050624","article-title":"Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment","volume":"39","author":"Rosenkranz","year":"1996","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.mcna.2016.01.005_bib57","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1464-5491.1991.tb01691.x","article-title":"Severe hypoglycaemia during treatment with glipizide","volume":"8","author":"Asplund","year":"1991","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.mcna.2016.01.005_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/17425250902806424","article-title":"Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions","volume":"5","author":"Holstein","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/j.mcna.2016.01.005_bib59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00228-003-0697-9","article-title":"Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy","volume":"59","author":"Holstein","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl","key":"10.1016\/j.mcna.2016.01.005_bib60","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF01218443","article-title":"Pharmacokinetics of glipizide in man: influence of renal insufficiency","volume":"9","author":"Balant","year":"1973","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib61","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc12-1365","article-title":"Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency","volume":"36","author":"Arjona Ferreira","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib62","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00007691-199610000-00017","article-title":"Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients","volume":"18","author":"Islam","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.mcna.2016.01.005_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabet.2010.09.003","article-title":"New-onset diabetes after transplantation: risk factors and clinical impact","volume":"37","author":"R\u00e4kel","year":"2011","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1399-0012.1998.tb01013.x","article-title":"Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients","volume":"12","author":"Sagedal","year":"1998","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.mcna.2016.01.005_bib65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/gerona\/glu072","article-title":"Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use","volume":"70","author":"Tan","year":"2015","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"10.1016\/j.mcna.2016.01.005_bib66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5414\/CNP60090","article-title":"Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure","volume":"60","author":"Inoue","year":"2003","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1016\/j.mcna.2016.01.005_bib67","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","article-title":"Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function","volume":"26","author":"Hasslacher","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib68","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1600-6143.2006.01250.x","article-title":"Repaglinide in the management of new-onset diabetes mellitus after renal transplantation","volume":"6","author":"T\u00fcrk","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.mcna.2016.01.005_bib69","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2005.07.005","article-title":"Cyclosporine markedly raises the plasma concentrations of repaglinide","volume":"78","author":"Kajosaari","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2016.01.005_bib70","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.2337\/dc11-s233","article-title":"Safety of PPAR agonists","volume":"34","author":"Home","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib72","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2125.2003.01785.x","article-title":"The pharmacokinetics of pioglitazone in patients with impaired renal function","volume":"55","author":"Budde","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.mcna.2016.01.005_bib73","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/01.TP.0000116393.98934.6F","article-title":"Rosiglitazone treatment of diabetes mellitus after solid organ transplantation","volume":"77","author":"Baldwin","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.mcna.2016.01.005_bib74","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/j.1600-6143.2004.00613.x","article-title":"Pioglitazone in the management of diabetes mellitus after transplantation","volume":"4","author":"Luther","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.mcna.2016.01.005_bib75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ndt\/gfh641","article-title":"Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients","volume":"20","author":"Voytovich","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.mcna.2016.01.005_bib76","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.mcna.2016.01.005_bib77","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.mcna.2016.01.005_bib78","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12020-014-0179-0","article-title":"Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature","volume":"46","author":"Giorda","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.mcna.2016.01.005_bib79","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1124\/dmd.112.045450","article-title":"Characterization of the in\u00a0vitro and in\u00a0vivo metabolism and disposition and cytochrome P450 inhibition\/induction profile of saxagliptin in humans","volume":"40","author":"Su","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.mcna.2016.01.005_bib80","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/TP.0b013e3182347ea4","article-title":"Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation","volume":"92","author":"Lane","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.mcna.2016.01.005_bib81","doi-asserted-by":"crossref","first-page":"617638","DOI":"10.1155\/2014\/617638","article-title":"Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation","volume":"2014","author":"Boerner","year":"2014","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.mcna.2016.01.005_bib82","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ndt\/gft536","article-title":"Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation","volume":"29","author":"Halden","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2016.01.005_bib83","doi-asserted-by":"crossref","first-page":"s203","DOI":"10.4103\/2230-8210.119572","article-title":"A\u00a0retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting","volume":"17","author":"Sanyal","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.mcna.2016.01.005_bib84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/dom.12176","article-title":"Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.mcna.2016.01.005_bib85","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.clinthera.2014.10.009","article-title":"Do dipeptidyl IV (DPP-IV) inhibitors cause heart failure?","volume":"36","author":"Clifton","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.mcna.2016.01.005_bib86","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.mcna.2016.01.005_bib87","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","article-title":"Effect of renal impairment on the pharmacokinetics of exenatide","volume":"64","author":"Linnebjerg","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.mcna.2016.01.005_bib88","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2125.2008.03221.x","article-title":"Exenatide may aggravate moderate diabetic renal impairment: a case report","volume":"66","author":"Johansen","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib89","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x","article-title":"Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide","volume":"68","author":"Jacobsen","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.mcna.2016.01.005_bib90","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2337\/dc13-2983","article-title":"Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study","volume":"38","author":"Thomsen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib91","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.2337\/dc13-1066","article-title":"Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series","volume":"36","author":"Pinelli","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mcna.2016.01.005_bib92","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.tp.0000251379.46596.2d","article-title":"Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes","volume":"83","author":"Ghofaili","year":"2007","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.mcna.2016.01.005_bib93","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/TP.0b013e31817c4ab3","article-title":"The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects","volume":"86","author":"Froud","year":"2008","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.mcna.2016.01.005_bib94","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.diabet.2014.10.004","article-title":"Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: a case series","volume":"41","author":"Cariou","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.mcna.2016.01.005_bib95","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000364909","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy","volume":"40","author":"Yamout","year":"2014","journal-title":"Am J Nephrol"},{"issue":"9","key":"10.1016\/j.mcna.2016.01.005_bib96","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.mcna.2016.01.005_bib97","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CP202158","article-title":"Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in health participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.mcna.2016.01.005_bib98","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2337\/diacare.14.4.344","article-title":"Severe hypoglycemia in type I diabetic patients with impaired kidney function","volume":"14","author":"Muhlhauser","year":"1991","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.mcna.2016.01.005_bib99","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-2003-37077","article-title":"Severe hypoglycemia in diabetics with impaired renal function","volume":"128","author":"Hasslacher","year":"2003","journal-title":"Dtsch Med Wochenschr"},{"issue":"10","key":"10.1016\/j.mcna.2016.01.005_bib100","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc12-0578","article-title":"A\u00a0randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency","volume":"35","author":"Baldwin","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.01.005_bib101","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ki.2014.70","article-title":"Enhanced posttransplant management of patients with diabetes improves patient outcomes","volume":"86","author":"Keddis","year":"2014","journal-title":"Kidney Int"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T20:52:23Z","timestamp":1748811143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712516000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0025712516000067"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2016.01.005","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes Care After Transplant","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2016.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}